This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steingrimsdottir, H.
Right arrow Articles by Eksborg, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steingrimsdottir, H.
Right arrow Articles by Eksborg, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2000, p. 207-209, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Bioavailability of Aciclovir after Oral Administration of Aciclovir and Its Prodrug Valaciclovir to Patients with Leukopenia after Chemotherapy

Hlif Steingrimsdottir,1 Astrid Gruber,1 Carina Palm,2 Gunnar Grimfors,1 Mats Kalin,3 and Staffan Eksborg2,*

Department of Medicine, Division of Hematology,1 Division of Infectious Diseases,3 and Karolinska Pharmacy,2 Karolinska Hospital, SE-171 76 Stockholm, Sweden

Received 14 June 1999/Returned for modification 1 August 1999/Accepted 25 October 1999

The median bioavailabilities of aciclovir after administration of aciclovir and its prodrug valaciclovir were 21.5 and 70.1%, respectively, in 12 patients with malignant hematological diseases with leukopenia after chemotherapy. The interindividual variations of the bioavailability were 48.5 and 21.0% after administration of aciclovir and valaciclovir, respectively. Neither the bioavailability nor the interindividual variation of area under the concentration-time curve of oral aciclovir or valaciclovir differed from that reported in healthy volunteers.

* Corresponding author. Mailing address: Karolinska Pharmacy, Karolinska Hospital, SE-171 76 Stockholm, Sweden. Phone: 468 51 77 53 30. Fax: 468 30 73 46. E-mail: stygge.staffan{at}swipnet.se.

Antimicrobial Agents and Chemotherapy, January 2000, p. 207-209, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Smolej, L. (2008). Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?. Blood 112: 2167-2167 [Full Text]  
  • Anand, B. S., Katragadda, S., Mitra, A. K. (2004). Pharmacokinetics of Novel Dipeptide Ester Prodrugs of Acyclovir after Oral Administration: Intestinal Absorption and Liver Metabolism. J. Pharmacol. Exp. Ther. 311: 659-667 [Abstract] [Full Text]  
  • Anand, B. S., Patel, J., Mitra, A. K. (2003). Interactions of the Dipeptide Ester Prodrugs of Acyclovir with the Intestinal Oligopeptide Transporter: Competitive Inhibition of Glycylsarcosine Transport in Human Intestinal Cell Line-Caco-2. J. Pharmacol. Exp. Ther. 304: 781-791 [Abstract] [Full Text]  
  • Dodd, D. A., Burger, J., Edwards, K. M., Dummer, J. S. (2001). Varicella in a Pediatric Heart Transplant Population on Nonsteroid Maintenance Immunosuppression. Pediatrics 108: e80-80 [Abstract] [Full Text]  
  • Hoglund, M., Ljungman, P., Weller, S. (2001). Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 47: 855-861 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»